Israel Englander Revance Therapeutics, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q2 2025

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	N/A	1,403,562 Added 949.57%	1,551,372 $3.99 Million
Q3 2024 Nov 14, 2024	SELL	$2.57 - $2.57 $1.57 Million - $1.57 Million	-609,102 Reduced 80.47%	147,810 $379,000
Q2 2024 Aug 14, 2024	BUY	$2.34 - $4.73 $1.41 Million - $2.86 Million	604,547 Added 396.78%	756,912 $1.95 Million
Q1 2024 May 15, 2024	BUY	$4.65 - $9.31 $647,326 - $1.3 Million	139,210 Added 1058.23%	152,365 $749,000
Q4 2023 Feb 14, 2024	SELL	$5.81 - $11.2 $1.93 Million - $3.72 Million	-332,303 Reduced 96.19%	13,155 $115,000
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $5.75 Million - $8.76 Million	232,891 Added 206.89%	345,458 $8.74 Million
Q1 2023 May 15, 2023	SELL	$18.36 - $35.27 $7.07 Million - $13.6 Million	-385,262 Reduced 77.39%	112,567 $3.63 Million
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $4.67 Million - $7.82 Million	255,146 Added 105.14%	497,829 $9.19 Million
Q3 2022 Nov 14, 2022	SELL	$14.33 - $28.47 $3.26 Million - $6.48 Million	-227,441 Reduced 48.38%	242,683 $6.55 Million
Q2 2022 Aug 15, 2022	BUY	$11.52 - $20.4 $3.88 Million - $6.87 Million	336,645 Added 252.21%	470,124 $6.5 Million
Q1 2022 May 16, 2022	BUY	$12.36 - $20.31 $1.65 Million - $2.71 Million	133,479 New	133,479 $2.6 Million
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $258,557 - $578,330	-20,751 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$25.78 - $33.21 $534,960 - $689,140	20,751 New	20,751 $578,000
Q2 2021 Aug 16, 2021	SELL	$26.8 - $31.84 $517,186 - $614,448	-19,298 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$24.03 - $29.97 $3 Million - $3.74 Million	-124,707 Reduced 86.6%	19,298 $539,000
Q4 2020 Feb 16, 2021	BUY	$23.41 - $28.34 $3.37 Million - $4.08 Million	144,005 New	144,005 $4.08 Million
Q1 2020 May 14, 2020	SELL	$12.46 - $27.81 $1.36 Million - $3.04 Million	-109,199 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$11.66 - $20.15 $1.27 Million - $2.2 Million	109,199 New	109,199 $1.77 Million
Q2 2019 Aug 14, 2019	SELL	$10.67 - $15.49 $332,455 - $482,637	-31,158 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$15.4 - $20.39 $5.55 Million - $7.35 Million	-360,391 Reduced 92.04%	31,158 $491,000
Q4 2018 Feb 14, 2019	SELL	$18.06 - $24.96 $4.32 Million - $5.97 Million	-239,107 Reduced 37.91%	391,549 $7.88 Million
Q3 2018 Nov 14, 2018	SELL	$23.55 - $30.1 $10.7 Million - $13.6 Million	-452,918 Reduced 41.8%	630,656 $15.7 Million
Q2 2018 Aug 14, 2018	SELL	$27.45 - $33.35 $11.3 Million - $13.7 Million	-410,867 Reduced 27.49%	1,083,574 $29.7 Million
Q1 2018 May 15, 2018	BUY	$29.15 - $37.4 $11.5 Million - $14.8 Million	395,409 Added 35.98%	1,494,441 $46 Million
Q4 2017 Feb 14, 2018	BUY	$24.55 - $36.3 $27 Million - $39.9 Million	1,099,032	1,099,032 $39.3 Million

Others Institutions Holding RVNC

# of Institutions

Shares Held

10.1M

Call Options Held

360K

Put Options Held

Black Rock Inc. New York, NY

8.57M
Shares

$22 Million
0.0% of portfolio
Nuveen Asset Management, LLC Chicago, IL

423K
Shares

$1.09 Million
0.0% of portfolio
Rothschild & CO Asset Management Us Inc. New York, NY

370K
Shares

$949,995
0.1% of portfolio
International Biotechnology Trust PLC London, X0

289K
Shares

$742,025
1.12% of portfolio
Credit Suisse Ag Zurich, V8

180K
Shares

$462,980
0.0% of portfolio

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account